Merck - 49 Year Stock Price History | MRK

Historical daily share price chart and data for Merck since 1970 adjusted for splits. The latest closing stock price for Merck as of September 13, 2019 is 82.61.
  • The all-time high Merck stock closing price was 94.88 on November 29, 2000.
  • The Merck 52-week high stock price is 87.35, which is 5.7% above the current share price.
  • The Merck 52-week low stock price is 66.10, which is 20% below the current share price.
  • The average Merck stock price for the last 52 weeks is 78.68.
Merck Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2019 80.7577 75.5900 86.9100 72.9200 82.6100 8.11%
2018 64.1581 56.2200 79.3400 53.2700 76.4100 35.79%
2017 62.2478 60.1500 66.5800 54.1000 56.2700 -4.42%
2016 57.4869 52.4800 64.9600 48.5900 58.8700 11.45%
2015 56.6162 57.1900 63.0300 48.4200 52.8200 -6.99%
2014 57.2076 49.4900 61.8800 49.4900 56.7900 13.47%
2013 46.4049 41.3400 50.1800 40.8500 50.0500 22.25%
2012 41.2774 38.3000 47.9600 37.1800 40.9400 8.59%
2011 34.1444 36.0400 37.9000 29.8100 37.7000 4.61%
2010 36.0341 37.0100 41.0300 31.8200 36.0400 -1.37%
2009 29.5741 31.0000 38.0000 20.9900 36.5400 20.20%
2008 37.1038 57.3700 60.5500 23.5600 30.4000 -47.69%
2007 50.6622 44.0200 60.7700 42.9400 58.1100 33.28%
2006 38.2875 32.7500 46.2100 32.7500 43.6000 37.06%
2005 30.6525 31.2600 34.9300 25.8500 31.8100 -1.03%
2004 42.0267 47.0500 49.0800 26.0000 32.1400 -30.43%
2003 53.2650 58.2500 63.2400 40.6000 46.2000 -18.39%
2002 54.0482 59.7600 64.3700 39.0500 56.6100 -3.72%
2001 71.2694 93.0000 93.0000 57.1700 58.8000 -37.20%
2000 73.7492 67.6300 94.8800 53.9400 93.6300 39.35%
1999 73.2395 74.9000 86.3800 60.9400 67.1900 -8.89%
1998 64.3975 53.8000 79.4500 51.4500 73.7500 39.15%
1997 47.2358 39.9400 53.6500 39.9400 53.0000 33.13%
1996 34.0199 32.1250 42.1250 28.5000 39.8100 21.32%
1995 24.7361 19.1900 33.4400 18.2500 32.8150 72.12%
1994 16.6396 17.6250 19.6900 14.1900 19.0650 10.91%
1993 17.5701 21.9400 21.9400 14.3750 17.1900 -20.75%
1992 24.2832 27.7300 28.1450 20.5650 21.6900 -21.84%
1991 19.9789 14.9167 27.7500 13.7083 27.7500 85.25%
1990 13.1712 13.1050 15.0417 11.1867 14.9800 15.97%
1989 11.7441 9.5417 13.3333 9.5417 12.9167 34.20%
1988 9.1213 9.1317 9.9167 8.0833 9.6250 9.31%
1987 9.3394 7.0000 12.0833 7.0000 8.8056 27.96%
1986 5.3114 3.8333 7.1944 3.7606 6.8817 80.83%
1985 3.0502 2.5869 3.8056 2.5106 3.8056 45.75%
1984 2.4617 2.5106 2.6944 2.2153 2.6111 4.00%
1983 2.5262 2.3333 2.8958 2.2778 2.5106 6.81%
1982 2.1355 2.3750 2.4375 1.7847 2.3506 -0.15%
1981 2.4145 2.3889 2.8439 2.1250 2.3542 0.00%
1980 2.0207 1.9653 2.3542 1.6319 2.3542 17.31%
1979 1.8755 1.8856 2.0519 1.7394 2.0069 6.85%
1978 1.5996 1.4894 1.9203 1.3369 1.8783 21.83%
1977 1.5599 1.8611 1.8611 1.3994 1.5417 -18.52%
1976 1.9866 1.9342 2.2328 1.7500 1.8922 -1.63%
1975 2.0687 1.8681 2.3750 1.6319 1.9236 4.32%
1974 1.9964 2.2328 2.3783 1.3611 1.8439 -17.80%
1973 2.4814 2.5139 2.7917 2.1597 2.2431 -9.39%
1972 2.1216 1.7396 2.4861 1.7396 2.4756 43.75%
1971 1.4723 1.3194 1.8160 1.3194 1.7222 25.25%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $211.513B $42.294B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $345.150B 15.03
Roche Holding AG (RHHBY) Switzerland $236.204B 0.00
Pfizer (PFE) United States $204.151B 12.02
Novartis AG (NVS) Switzerland $199.581B 17.16
Novo Nordisk (NVO) Denmark $117.216B 20.71
AstraZeneca (AZN) United Kingdom $112.218B 21.71
Sanofi (SNY) France $109.456B 13.45
Eli Lilly (LLY) United States $107.057B 19.98
AbbVie (ABBV) United States $104.248B 8.35
GlaxoSmithKline (GSK) United Kingdom $101.988B 12.82
Bristol-Myers Squibb (BMY) United States $80.856B 11.47
Bayer (BAYRY) Germany $70.165B 10.22
H Lundbeck (HLUYY) Denmark $6.958B 10.04